IP Library › Patent Application 13623674
Patent Application
App. No. 13/623,674

METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/623,674
Abstract

A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Claims (71)

1 . A β-D-2′-deoxy-2′-halo-2′-C-methyl-nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

2 . The deoxynucleoside of claim 1 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl-nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

3 . The deoxynucleoside of claim 1 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methylpyrimidine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

4 . The deoxynucleoside of claim 1 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methylpyrimidine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

5 . The deoxynucleoside of claim 3 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl uracil nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

6 . The deoxynucleoside of claim 3 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl uracil nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

7 . The deoxynucleoside of claim 3 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl cytosine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

8 . The deoxynucleoside of claim 3 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl cytosine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

9 . The deoxynucleoside of claim 1 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl-ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

10 . The deoxynucleoside of claim 9 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methylpyrimidine ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

11 . The deoxynucleoside of claim 10 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl uracil ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

12 . The deoxynucleoside of claim 10 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl cytosine ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

13 . A pharmaceutical composition comprising the deoxynucleoside of claim 1 and a pharmaceutically acceptable excipient.

14 . The pharmaceutical composition of claim 13 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl-nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

15 . The pharmaceutical composition of claim 13 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methylpyrimidine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

16 . The pharmaceutical composition of claim 13 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methylpyrimidine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

17 . The pharmaceutical composition of claim 15 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl uracil nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

18 . The pharmaceutical composition of claim 15 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl uracil nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

19 . The pharmaceutical composition of claim 15 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl cytosine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

20 . The pharmaceutical composition of claim 15 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl cytosine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

21 . The pharmaceutical composition of claim 13 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl-ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

22 . The pharmaceutical composition of claim 21 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methylpyrimidine ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

23 . The pharmaceutical composition of claim 22 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl uracil ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

24 . The pharmaceutical composition of claim 22 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl cytosine ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

25 . The pharmaceutical composition of claim 13 , wherein the composition is formulated as a dosage unit for single dose administration.

26 . The pharmaceutical composition of claim 25 , wherein the dosage unit contains from about 50 to about 1000 mg of the deoxynucleoside.

27 . The pharmaceutical composition of claim 25 , wherein the dosage unit is a tablet or capsule.

28 . A method for the treatment of a hepatitis C virus infection in a host, comprising administering to the host an antivirally effective amount of a deoxynucleoside, wherein the deoxynucleoside is a β-D-2′-deoxy-2′-C-methyl-nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

29 . The method of claim 28 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl-nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

30 . The method of claim 28 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl-nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

31 . The method of claim 28 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-C-methyl pyrimidine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

32 . The method of claim 31 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methylpyrimidine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

33 . The method of claim 31 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methylpyrimidine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

34 . The method of claim 31 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-C-methyl uracil nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

35 . The method of claim 31 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl uracil nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

36 . The method of claim 35 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl uracil nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

37 . The method of claim 31 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-C-methyl cytosine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

38 . The method of claim 31 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl cytosine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

39 . The method of claim 38 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl cytosine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

40 . The method of claim 28 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl-ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

41 . The method of claim 40 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methylpyrimidine ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

42 . The method of claim 41 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl uracil ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

43 . The method of claim 41 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl cytosine ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

44 . The method of claim 28 , wherein the host is a human.

45 . The method of claim 28 , wherein the antivirally effective amount is ranging from about 0.1 to about 100 mg/kg/day.

46 . The method of claim 45 , wherein the antivirally effective amount is ranging from about 1 to about 50 mg/kg/day.

47 . The method of claim 45 , wherein the antivirally effective amount is ranging from about 1 to about 20 mg/kg/day.

48 . The method of claim 28 , wherein the deoxynucleoside is administered in combination or alternation with a second anti-hepatitis C agent.

49 . The method of claim 48 , wherein the second agent is selected from the group consisting of an interferon, ribavirin, a protease inhibitor, a thiazolidine derivative, a polymerase inhibitor, and a helicase inhibitor.

50 . The method of claim 48 , wherein the second agent is an interferon.

51 . The method of claim 48 , wherein the second agent is ribavirin.

52 . 2′-C-Methyl-guanosine, or a pharmaceutically acceptable salt or prodrug thereof.

53 . 2′-C-Methyl-guanosine monophosphate, diphosphate, or triphosphate.

54 . A pharmaceutical composition comprising the 2′-C-methyl-guanosine of claim 52 and a pharmaceutically acceptable excipient.

55 . A method for inhibiting replication of a hepatitis C virus in a host, comprising contacting the host with an antivirally effective amount of a deoxynucleoside, wherein the deoxynucleoside is a β-D-2′-deoxy-2′-C-methyl-nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

56 . The method of claim 55 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl-nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

57 . The method of claim 55 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl-nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

58 . The method of claim 55 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-C-methyl pyrimidine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

59 . The method of claim 55 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methylpyrimidine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

60 . The method of claim 59 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methylpyrimidine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

61 . The method of claim 58 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-C-methyl uracil nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

62 . The method of claim 61 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl uracil nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

63 . The method of claim 61 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl uracil nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

64 . The method of claim 58 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-C-methyl cytosine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

65 . The method of claim 64 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl cytosine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

66 . The method of claim 64 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-fluoro-2′-C-methyl cytosine nucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

67 . The method of claim 56 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl-ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

68 . The method of claim 67 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methylpyrimidine ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

69 . The method of claim 68 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl uracil ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

70 . The method of claim 68 , wherein the deoxynucleoside is a β-D-2′-deoxy-2′-halo-2′-C-methyl cytosine ribonucleoside, or pharmaceutically acceptable salt or a prodrug thereof.

71 . The method of claim 55 , wherein the host is a human cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2012
From: SOMMADOSSI, JEAN-PIERRE; LACOLLA, PAOLO
To: IDENIX PHARMACEUTICALS, INC.
Reel/Frame 029464/0171 →